CREBBP and plasma cell myeloma: The PROTAC dCBP-1 is based on the CBP/EP300 ligand GNE-781, a recently described CBP/EP300 bromodomain inhibitor that is potent and selective against multiple myeloma cells by abolishing the MYC enhancer [111].